Diagnostic criteria for lung-dominant connective tissue disease.

<p>Criteria derived from Reference 11.</p><p>ANA: antinuclear antibody; RF: rheumatoid factor; CCP: cyclic citrullinated peptide; Scl-70: Sclero 70; ds DNA: double-stranded DNA; RNP: ribonucleoprotein.</p><p>Diagnostic criteria for lung-dominant connective tissue disease.</p

Autoantibody profile of the study cohort.

<p>Data are presented as number. Some patients had multiple positive serological tests.</p><p>Autoantibody profile of the study cohort.</p

Results of stepwise multivariate Cox proportional hazard model.

<p>Used for variables that were significant in univariate analysis (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0108339#pone-0108339-t004" target="_blank">Table 4</a>).</p><p>FVC, DLCO, PaO₂, 6MWD, Lowest SpO₂, MPAP.</p><p>Results of stepwise multivariate Cox proportional hazard model.</p

Histogram of MPAP.

<p>Histogram of MPAP.</p

Baseline characteristics and physiology of patients with and without PH.

<p>Data are presented as means ± SD or numbers.</p><p>N = 100 except for FVC (n = 99), DLCO (n = 96), MMRC (n = 95), 6MWD (n = 91), Lowest SpO2 (n = 91).</p><p>Baseline characteristics and physiology of patients with and without PH.</p

Kaplan-Meier curves for survival according to MPAP (p = 0.005).

<p>Survival curves were compared with log-rank statistics.</p

Results of the univariate Cox proportional hazard model.

<p>HR: hazard ratio; CI: confidence interval.</p><p>Results of the univariate Cox proportional hazard model.</p

Baseline characteristics.

<p>Data are presented as means ± SD or numbers.</p><p>BMI: body mass index; FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide; MMRC: Modified Medical Research Council Dyspnea Scale; 6MWD: 6 minute walk distance; MPAP: mean pulmonary artery pressure; PAWP: pulmonary artery wedge pressure; PVR: pulmonary vascular resistance.</p><p>N = 100 except for FVC (n = 99), DLCO (n = 96), MMRC (n = 95), 6MWD (n = 91), Lowest SpO2 (n = 91).</p><p>Baseline characteristics.</p

Screening and inclusion process for patients in the study.

<p>Screening and inclusion process for patients in the study.</p